A translational perspective on advancing nanoparticle drug-delivery systems from laboratory development toward clinical implementation is provided, with particular emphasis on computational modeling, artificial intelligence, and digital twins for formulation optimization and personalized nanomedicine.
Abstract
Nanoparticle-based drug delivery systems have become an important component of modern nanomedicine, enabling improved drug protection, controlled release, targeted delivery, and the modulation of pharmacokinetic behavior. Their therapeutic performance is governed by physicochemical properties such as size, shape, surface chemistry, and material composition, which influence biological interactions, biodistribution, cellular uptake, and clearance. This review examines major nanoparticle platforms, including polymeric, lipid-based, inorganic, carbon-based, and hybrid systems, together with passive and active targeting and endogenous and externally triggered release strategies. Current and emerging applications in oncology, infectious diseases, central nervous system disorders, gene therapy, and vaccines are discussed alongside theranostic and combination-delivery approaches. Particular emphasis is placed on computational modeling, artificial intelligence, and digital twins for formulation optimization and personalized nanomedicine. Key barriers to clinical translation, including manufacturing scalability, biological variability, limitations of EPR-mediated targeting, regulatory standardization, and long-term safety, are critically evaluated. Finally, emerging directions in sustainable nanomanufacturing and biomimetic delivery are discussed. By integrating biological mechanisms with computational, manufacturing, regulatory, and clinical considerations, this review provides a translational perspective on advancing nanoparticle drug-delivery systems from laboratory development toward clinical implementation.
Liposomes are versatile nanocarrier systems widely investigated for pharmaceutical drug delivery because of their biocompatibility, biodegradability, and ability to encapsulate both hydrophilic and lipophilic drugs. Since their discovery in the 1960s, liposomes have evolved into advanced nanomedicine platforms with app...
Shubham Sachdeva, Vikramjit Singh, Harwinder Kaur et al.· Journal of Drug Delivery and...· 0 citations
Despite significant advances in technology and medical sciences, and substantial investment in drug discovery by the pharmaceutical industry, the clinical success of therapeutic agents for cancer and chronic diseases remains limited. Poor aqueous solubility, low bioavailability, rapid systemic clearance, and restricted...
Mohammed Muqtader Ahmed· Natural Resources for Human...· 0 citations
Cancer remains a major global health challenge, and nanoparticle-based drug delivery systems have emerged as a promising strategy for targeted cancer therapy. However, clinical translation is still limited by an incomplete understanding of how nanoparticles navigate the tumor microenvironment (TME) throughout the deliv...
Meng-Xin Ban, Si-Fang Zhao, Zi-Yu Liu et al.· Pharmaceutics· 0 citations
Smart nanoformulations have emerged as promising platforms in precision medicine by enabling controlled drug delivery, improved therapeutic targeting, enhanced bioavailability, and potential reductions in systemic toxicity. Conventional drug delivery systems often encounter limitations associated with poor aqueous solu...
A. Sonia, A. Ansar, D. Jayachandran et al.· International Journal of Dru...· 0 citations
This review paper provides an integrated and critical perspective on next-generation nanomedicine by connecting nanocarrier design with tumor-specific accumulation, intracellular trafficking, stimuli-responsive drug release, combination therapy and clinical translation.
Biswajit Mohanty, P. Saikia, Piyush Pandey et al.· Frontiers in Chemistry· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.